Jan. 12 at 1:51 PM
$HOWL Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and next-generation INDUCER T cell engager platform. Management said they observed strong monotherapy and combination activity with WTX-124 in heavily pretreated melanoma, cutaneous squamous cell carcinoma, and gastroesophageal junction cancer, with objective response rates of 21-30% in select populations. Tumor regression in roughly 33% of lesions was reported, alongside a favorable tolerability profile, including no vascular leak syndrome and manageable grade 3-4 adverse events (27/106 and 2/106). Moreover, the FDA accepted 18mg as the recommended dose, providing guidance for a monotherapy registration path in relapsed/refractory melanoma.
https://finance.yahoo.com/news/werewolf-therapeutics-howl-eyes-2026-092347628.html
